Annals of Emergency Medicine
Volume 37, Issue 2 , Pages 202-216 , February 2001

Treatment of acute ischemic stroke

  • Christopher Lewandowski, MD

      Affiliations

    • Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, and Case Western Reserve University, Cleveland, OH
    • ,
  • William Barsan, MD

      Affiliations

    • Department of Emergency Medicine, University of Michigan, Ann Arbor, MI.

Received 17 September 1999 ,Revised 2 August 2000 ,Accepted 28 August 2000.

References 

  1. American Heart Association . 2000 Heart and Stroke Statistical Update. In: Dallas, TX: : American Heart Association; 1999;p. 13–14
  2. Adams HP. Treating ischemic stoke as an emergency. Arch Neurol. 1998;55:457–461
  3. Major ongoing stroke trials . Stroke. 2000;31:557–562
  4. Jones TH, Morawetz RB, Crowell RM, et al.  Thresholds of focal ischemia in awake monkeys. J Neurosurg. 1981;54:773–782
  5. Pulsinelli WA. The ischemic penumbra in stroke. Sci Med. 1995;1:16–25
  6. Hakim AM. Ischemic penumbra, the therapeutic window. Neurology. 1998;51(Suppl 3):S44–S46
  7. Astrup J, Seisjo BK, Symon L. Thresholds in cerebral ischemia—the ischemic penumbra. Stroke. 1981;12:723–725
  8. Zivin JA, Choi DW. Stroke therapy. Sci Am. 1991;265:56–63
  9. DeGraba TJ. The role of inflammation after acute stroke, utility of pursuing anti-adhesion molecule therapy. Neurology. 1998;(Suppl 3):S62–S68
  10. Choi DW. Ischemia-induced neural apoptosis. Curr Opin Neurobiol. 1996;6:667–672
  11. The Multicenter Acute Stroke Trail-Europe Study Group . Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145–150
  12. Multicenter Acute Stroke Trail-Italy (MAST-I) Group . Randomize controlled trial of streptokinase aspirin and combination of both in treatment of acute ischemic stroke. Lancet. 1995;346:1509–1514
  13. Donnan GA, Davis SM, Chambers BR, et al.  For the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA. 1996;276:961–966
  14. Hacke W, Kaste M, Fieschi C, et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA. 1995;274:1017–1025
  15. National Institute of Neurologic Disorders in Stroke rt-PA Stroke Study Group . Tissue plasmigin activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  16. Hacke W, Kste M, Fieschi C, et al.  Randomized double blind placebo control trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS-2). Lancet. 1998;352:1245–1251
  17. Clark WM, Wissman S, Albers GW, et al.  Recombinant tissue plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset, The ATLANTIS Study: a randomized controlled trial. JAMA. 1999;282:2019–2026
  18. Shermann DG, Atkinson RP, Chippendale T, et al.  Intravenous Ancrod for treatment of acute ischemic stroke The STAT Study: a randomized controlled trial. JAMA. 2000;283:2395–2403
  19. International Stroke Trial Collaborative Group . The international stroke trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569–1581
  20. CAST (Chinese Acute Stroke Trial) Collaborative Group . CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349:1641–1649
  21. The NINDS t-PA Study Group . Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109–2118
  22. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators . Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke. A Randomized Controlled Trial. JAMA. 1998;279:1265–1272
  23. del Zoppo GJ. Clinical trials in acute stroke. Why have they not been successful?. Neurology. 1998;51(Suppl 3):S59–S61
  24. del Zoppo GJ, Higashida RT, Furlan AJ, et al.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29:4–11
  25. Ferland AJ, Higashida R, Wechsler L, et al.  Intra-arterial Prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. JAMA. 1999;282:2003–2011
  26. TIMI Study Group . The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932–936
  27. Egan R, Clark W, Lutsep H, et al.  Efficacy of intra-arterial thrombolysis of basilar artery stroke. J Stroke Cerebrovasc Dis. 1999;8:22–27
  28. Ferbert A, Bruckman H, Drummen R. Clinical features of proven basilar occlusion. Stroke. 1990;21:1135–1142
  29. Hacke W, Zeumer H, Ferbert A, et al.  Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988;19:1216–1222
  30. Lewandowski CA, Frankel M, Tomsick TA, et al.  Combined intravenous and intra-arterial r-tPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598–2605
  31. Lewandowski CA, Libman R. Acute presentation of stroke. J Stroke Cerebrovasc Dis. 1999;8:117–126
  32. Brott T, Adams HP, Olinger CP, et al.  Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–870
  33. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol. 1989;46:660–662
  34. Adams HP, Brott TG, Crowell RM, et al.  Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke. 1994;25:1901–1914
  35. Culbras A, Kase CS, Masdeu JC, et al.  Practice guidelines for the use of imaging and transient ischemic attacks in acute stroke. Report of the Stroke Council, American Heart Association. Stroke. 1997;28:1480–1497
  36. Mohr JP, Biller J, Alou SK, et al.  Magnetic resonance versus computed tomographic imaging in acute stroke. Stroke. 1995;26:807–812
  37. von Kummer R, Meyding-Lamade U, Forsting M, et al.  Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol. 1994;15:9–15
  38. Marks MP, Holmgren EB, Fox AJ, et al.  Evaluation of early computed tomographic findings in acute ischemic stroke. Stroke. 1999;30:389–392
  39. von Kummer R, Webber J. Brain and vascular imaging in acute ischemic stroke: the potential of computed tomography. Neurology. 1997;49(Suppl 4):s52–s55
  40. Tomsick T, Brott T, Barson W, et al.  Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultra early thrombolytic therapy. AJNR Am J Neuroradiol. 1996;17:79–85
  41. Wildermuth S, Knauth M, Brandt T, et al.  Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke. Stroke. 1998;29:935–938
  42. Koenig M, Klotz E, Luka B, et al.  Perfusion CT of the brain diagnostic approach for early detection of ischemic stroke. Radiology. 1998;209:85–93
  43. Na DG, Buyun HS, Lee KH, et al.  Acute occlusion of the middle cerebral artery: early evaluation of tri-phase echolocation CT, preliminary results. Radiology. 1998;207:113–122
  44. Firlik AD, Kaufmann AM, Wechsler LR, Firlik KS, Fukui MB, Yonas H. Quantitative cerebral bloodflow determinations in acute ischemic stroke relationship to computed tomography and angiography. Stroke. 1997;28:2208–2213
  45. Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke. JAMA. 1995;274:908–911
  46. Albers GW. Diffusion weighted MRI for evaluation of acute stroke. Neurology. 1998;51(Suppl 3):s47–s49
  47. Fisher M, Albers GW. Applications of diffusion perfusion magnetic resonance imaging in acute ischemic stroke. Neurology. 1999;52:1750–1756
  48. Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology. 1993;43:461–467
  49. Broderick J, Brott T, Barsan W, et al.  Blood pressure during the first minutes of focal cerebral ischemia. Ann Emerg Med. 1993;22:1438–1443
  50. Adams HP, Brott TG, Furlan AJ, et al.  Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation. 1996;94:1167–1174
  51. McDowell FH, Brott TG, Goldstein M, et al.  Stroke: the first hours, emergency evaluation, and treatment. National Stroke Association Consensus Statement. Stroke Clinical Update. 1997;1–14 (Special edition)
  52. Lisk DR, Grotta JC, Lamki LM, et al.  Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol. 1993;50:855–862
  53. Dimant J, Grob D. Electrocardiographic changes and myocardial damage in patients with acute cerebrovascular accidents. Stroke. 1977;8:448–455
  54. The Hemodilution in Stroke Study Group . Hypervolemic hemodilution treatment of acute stroke. Stroke. 1989;20:317–323
  55. Wass CT, Lanier WL. Glucose modulation of ischemic brain injury: review and clinical recommendations. Mayo Clin Proc. 1996;71:801–812
  56. Bruno A, Biller J, Adams HP, et al.  Acute blood glucose level and outcome from ischemic stroke. Neurology. 1999;52:280–284
  57. Reith J, Jorgensen HS, Pedersen PM, et al.  Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996;347:422–425
  58. Schwab S, Spranger M, Aschoff A, et al.  Brain temperature monitoring and modulation in patients with severe MCA infarction. Neurology. 1997;48:762–767
  59. Reith J, Jorgensen HS, Nakayama H, et al.  Seizures in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke. 1997;28:1585–1589
  60. The NINDS t-PA Study Group . Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA stroke trial. Stroke. 1997;28:2119–2125
  61. Haley EC, Lewandowski C, Tilley BC, et al.  Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med. 1997;30:676–682
  62. North American Symptomatic Carotid Endarterectomy Trial Collaborators . Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–453
  63. Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med. 1994;154:1443–1448
  64. Fagan SC, Morgenstern LB, Pettita A, et al.  Cost effectiveness of tissue plasminogen activator for ischemic stroke. Neurology. 1998;50:882–900
  65. Report of the Quality Standards Subcommittee of the American Academy of Neurology . Practice advisory: thrombolytic therapy for acute ischemic stroke—summary statement. Neurology. 1996;47:835–839
  66. Wester P, Radgerg J, Lundgren B, et al.  Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA. A prospective, multicenter trial. Stroke. 1999;30:40–48
  67. Stroke Unit Trialists’ Collaboration . Collaborative systematic review of the randomized trials of organized inpatient (stroke unit) care after stroke. BMJ. 1997;314:1151–1159
  68. Alberts M, Hademenos G, Latchaw RE, et al.  Recommendations for the establishment of primary stroke centers. JAMA. 2000;283:3102–3109
  69. In:  Marler JR,  Winters-Jones P,  Emr M editor. National Institute of Neurological Disorders and Stroke, Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, MD: : National Institutes of Health; 1997;p. 157–158 [NIH publication No. 97-4239]
  70. The NINDS rt-PA Stroke Study Group . A systems approach to immediate evaluation and management of hyperacute stroke: experience at 8 centers and implications for community practice and patient care. Stroke. 1997;28:1530–1540
  71. Tilley BC, Lyden PD, Brott TG, et al.  Total quality improvement methodology reduces delays between emergency department admission and treatment of acute ischemic stroke. Arch Neurol. 1997;54:1466–1474
  72. Albers GW, the STARS Investigators . Prospective, monitored, multicenter, post-approval experience with intravenous t-PA for treatment of acute stroke: the standard treatment with activase to reverse stroke (STARS) study [abstract]. Stroke. 1999;30:244
  73. Katzan IL, Furlan AJ, Lloyd LE, et al.  Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland experience. JAMA. 2000;283:1151–1158
  74. Grond M, Stenzel C, Schmulling S, et al.  Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke. 1998;29:1544–1549
  75. Tanne D, Bates VE, Verro P, et al.  Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology. 1999;53:424–427
  76. Smith RW, Scott PA, Grant RJ, et al.  Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis. Acad Emerg Med. 1999;6:618–625
  77. Chiu D, Krieger D, Villar-Cordova C, et al.  Intravenous tissue plasminogen activator for acute ischemic stroke. Feasibility, safety, and efficacy in the first year of clinical practice. Stroke. 1998;29:18–22
  78. Buchan AM, Barber PA, Newcommon N, et al.  Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology. 2000;54:679–684
  79. Wang DZ, Rose JA, Honings DS, et al.  Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke. 2000;31:77–81
  80. Tanne D, Gorman MJ, Bates VE, et al.  Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke. 2000;31:370–375
  81. del Zoppo GJ, Wagner S, Tagaya M. Trends and future developments in the pharmacologic treatment of acute ischemic stroke. Drugs. 1997;54:9–38
  82. Nakano S, Yokogami K, Ohata H, et al.  Direct percutaneous transluminal angioplasty for acute middle cerbral artery occlusion. AJNR Am J Neuroradiol. 1998;19:767–772
  83. Baird AE, Warach S. Using pathophysiology in acute stroke trials [editorial]. Stroke. 1999;30:1293

☆ Editor’s Note: This article continues a series of special contributions addressing state-of-the-art techniques, topics, or concepts. State-of-the-art articles will be featured in Annals on a regular basis in the next several volumes.

☆☆ Address for reprints: Christopher Lewandowski, MD, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI 48202;,313-916-1553, fax 313-916-7437;,E-mail clewand1@hfhs.org .

PII: S0196-0644(01)09861-4

doi: 10.1067/mem.2001.111573

Annals of Emergency Medicine
Volume 37, Issue 2 , Pages 202-216 , February 2001

Article Tools